» Articles » PMID: 34139285

Cancer-associated Fibroblasts Induce Monocytic Myeloid-derived Suppressor Cell Generation Via IL-6/exosomal MiR-21-activated STAT3 Signaling to Promote Cisplatin Resistance in Esophageal Squamous Cell Carcinoma

Overview
Journal Cancer Lett
Specialty Oncology
Date 2021 Jun 17
PMID 34139285
Citations 65
Authors
Affiliations
Soon will be listed here.
Abstract

Drug resistance remains the major obstacle limiting the effectiveness of chemotherapy for esophageal squamous cell carcinoma (ESCC)[1]. However, how stromal cells cooperate with immune cells to contribute to drug resistance is not yet fully understood. In this study, we observed that monocytic myeloid-derived suppressor cells (M-MDSCs) were correlated with cisplatin resistance in patients with ESCC. Furthermore, CAFs promoted differentiation of monocytes into M-MDSCs phenotypically and functionally in vitro. Mechanically, both interleukin (IL)-6 and exosome-packed microRNA-21 (miR-21) secreted by CAFs synergistically promoted the generation of M-MDSCs via activating the signal transducing activator of transcription 3 (STAT3) by IL-6 in an autocrine manner. Combined blocking of IL-6 receptor and inhibition of miR-21 significantly reversed CAF-mediated M-MDSC generation. Notably, the effects of CAFs on M-MDSC induction were abolished by inhibiting STAT3 signaling. Functionally, CAF-induced M-MDSCs promoted drug resistance of tumor cells upon cisplatin treatment. Clinically, ESCC patients with high infiltration of CAFs and CD11b myeloid cells had unfavorable predicted overall survival both in our cohort and in TCGA data. Taken together, our study reveals a paracrine and autocrine of IL-6 caused by CAFs co-activate STAT3 signaling, promoting the generation of M-MDSCs, and highlights the important role of CAFs in cooperation with M-MDSCs in promoting drug resistance, thus providing potential opportunities for reversing drug resistance through inhibition of STAT3 signaling.

Citing Articles

Single-cell transcriptomic analyses reveal heterogeneity and key subsets associated with survival and response to PD-1 blockade in cervical squamous cell carcinoma.

Li X, Zhao Z, Cheng Y, Yan J, Ren F, Jia Y Cancer Cell Int. 2025; 25(1):90.

PMID: 40082876 PMC: 11907857. DOI: 10.1186/s12935-025-03725-x.


Regulation of cancer-associated fibroblasts for enhanced cancer immunotherapy using advanced functional nanomedicines: an updated review.

Liao T, Chen X, Qiu F, Zhang X, Wu F, Zhao Z J Nanobiotechnology. 2025; 23(1):166.

PMID: 40038745 PMC: 11877876. DOI: 10.1186/s12951-025-03217-0.


Extracellular vesicles in tumor immunity: mechanisms and novel insights.

Kuang L, Wu L, Li Y Mol Cancer. 2025; 24(1):45.

PMID: 39953480 PMC: 11829561. DOI: 10.1186/s12943-025-02233-w.


Flow cytometry immune profiling of recurrent and newly diagnosed growth hormone secreting pituitary neuroendocrine tumors: comparison of two clinical cases.

Lisina D, Mazeeva V, Zakharova E, Sorokina A, Dzhemileva L, Grigoriev A BMC Endocr Disord. 2025; 25(1):37.

PMID: 39939927 PMC: 11816545. DOI: 10.1186/s12902-025-01865-9.


Cancer-associated fibroblast-derived extracellular vesicles: regulators and therapeutic targets in the tumor microenvironment.

Xie J, Lin X, Deng X, Tang H, Zou Y, Chen W Cancer Drug Resist. 2025; 8:2.

PMID: 39935427 PMC: 11810458. DOI: 10.20517/cdr.2024.152.